Sugammadex + Neostigmine + Atropine + Rocuronium + Fentanyl + Propofol + Sevoflurane
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Post-operative Residual Curarization
Conditions
Post-operative Residual Curarization
Trial Timeline
Nov 1, 2014 → Jul 1, 2017
NCT ID
NCT02698969About Sugammadex + Neostigmine + Atropine + Rocuronium + Fentanyl + Propofol + Sevoflurane
Sugammadex + Neostigmine + Atropine + Rocuronium + Fentanyl + Propofol + Sevoflurane is a approved stage product being developed by Merck for Post-operative Residual Curarization. The current trial status is unknown. This product is registered under clinical trial identifier NCT02698969. Target conditions include Post-operative Residual Curarization.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02698969 | Approved | UNKNOWN |
Competing Products
18 competing products in Post-operative Residual Curarization